China's cell therapy biotechnology company, Sibbi Biotech Group, announced on the 11th that it has signed a strategic cooperation framework agreement with GE Healthcare, the world's largest biopharmaceutical and medical technology service provider, to be based in Sibman. The Shanghai Zhangjiang Production Base established a joint laboratory to promote the industrial production of cell therapeutic preparations. According to Reuters Shanghai on April 11, the company's press release said that the joint laboratory will jointly develop high-quality industrial production processes for chimeric antigen receptor T cells (CAR-T cells) and stem cells; The Technology Development Center has established an advanced automated production system at the GMP drug production bases in Sibman in Shanghai, Wuxi and Beijing. By the end of the year, Sibman has a total area of ​​nearly 7,000 square meters of GMP production facilities in Shanghai and other three places. The cell production capacity can not only support the existing five cell products developed for clinical trials, but also full capacity. Support the annual production requirements for 10,000 cancer patients and 10,000 bone and joint patients each year. Liu Bizuo, CEO of Siebel Group, said, “We clearly understand that the most difficult part of developing immuno-oncology and stem cell therapy technology will be the transformation from laboratory research and exploration to industrial production, namely automation and standardization. And a complete quality control system." Sibman is the only Chinese cell therapy biotechnology company listed on NASDAQ. At present, tumor immunocytotherapy as an individual treatment, in order to ensure the quality standards and treatment processes of industrialization, the production process requirements are very high. Sibman closed at $11.55 on the 10th, up 4.05%. Sibman told the reporters that the strategic cooperation with GE Healthcare will help to strengthen the independent production capacity of Sibman, and develop CAR-T products from the laboratory through closed and automated production systems. The stage quickly and effectively enters the industrial production stage of clinical trials, drug declarations and product launches. Cell therapy is one of the priorities of GE's life sciences business. In this area, GE's strategy is to fully cooperate with industry and partners to build a comprehensive digital ecosystem including cell therapy tools, solutions and services to accelerate the industry. Standardization and integration to help customers bring new therapeutic technologies to the clinic.
Natural Plant Extract is a kind of solid powder obtained by cleaning, extracting, concentrating and spray drying Chinese herbal fruits and vegetables, without adding any other ingredients; The effective components and essence of plants are extracted, which improves the full utilization rate of plants and is beneficial to human absorption.
The components of plant extracts can be divided into glycosides, acids, polyphenols, polysaccharides, terpenoids, flavonoids, alkaloids and so on. For example, the main component of green tea extract is tea polyphenols. Ginseng extract mainly contains a variety of ginseng monomer saponins; According to different characters, it can be divided into extract, powder, lens, etc., such as violet leaf extract, hang white chrysanthemum extract. Natural Plant Extract,Paeony Extract,Licorice Root Extract,Dong Quai Root Extract Fufeng Sinuote Biotechnology Co.,Ltd. , https://www.sinuotebio.com